Navigation Links
Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials

ivision of Cardiology at the Tufts-New England Medical Center, and professor of Medicine at Tufts University School of Medicine, Boston, Mass. Konstam presented the short- and long-term EVEREST data analyses during a late-breaker session Sunday, March 25 at the ACC. "In the long-term trial, tolvaptan neither statistically improved nor worsened survival relative to placebo. The EVEREST data suggest that tolvaptan may be a potential therapy for patients with heart failure."

Tolvaptan is a novel, investigational small molecule designed to be an antagonist of the vasopressin V2 receptor, which plays a role in the kidney's regulation of fluid excretion. The majority of patients hospitalized for ADHF, the worsening of chronic HF that affects 1 million U.S. residents annually,(3) have edema or excess body fluid, which is treated with diuretics to excrete the fluid. In contrast to diuretics, tolvaptan is designed to promote aquaresis, the excretion of electrolyte-free water.(1) Otsuka Pharmaceutical Co., Ltd. (Japan) and Otsuka Pharmaceutical Development & Commercialization, Inc., are developing tolvaptan, which has the potential to be the first available oral vasopressin receptor antagonist.(4,5)

Short-Term Studies: Pre-Specified Secondary Endpoints

In the two short-term studies, reductions in average body weight at day seven or discharge were statistically significantly different between the tolvaptan group versus the placebo group, 3.35 kilograms (kg) and 2.73 kg, respectively, in study A (p less than 0.001) and 3.77 kg and 2.79 kg, respectively, in study B (p less than 0.001). In addition, the use of tolvaptan significantly reduced patients' body weight as early as on the first day of treatment in both short-term studies (p less than 0.001).(1) There was no significant difference between the treatment groups in improvement in patient-assessed global clinical status at day 7 or discharge, if earlier; however the changes were numerically in favor
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
3. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
4. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
7. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
8. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
9. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
10. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
11. UCB Presents Long-Term CImzia Data in Crohns Disease

Post Your Comments:
(Date:11/5/2009)...Nov. 5 Jazz Pharmaceutic...al results for the third quarter ended September 3...er of 2009 were $30.8 million, compared to $17.7 m...YREM® (sodium oxybate) oral solution net sale..., compared to $14.2 million for the third quarter ...
(Date:11/5/2009).... 5 Virtual Health Techn... today that it has entered into a Letter of Intent...anagement Technologies, Inc. (WNDM). The deal prov...bt, 4,000,000 shares of WNDM stock and a royalty a...sed at $2.00 per share on 11/4/09 and VHGI closed ...
(Date:11/5/2009)..., Calif., Nov. 5 Sunesis...unced that the U.S. Food and Drug Administration h...he treatment of acute myeloid leukemia (AML). Sune...rials of voreloxin in AML: a single-agent study, k...elderly AML patients unlikely to benefit from stan...
Breaking Medicine Technology:Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 2Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 3Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 4Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 5Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 7OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 2OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 3Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses 13096 1Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses 13096 2Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses 13096 3Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 1Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 2Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 3Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 4Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 5Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus 28R 29 in Head to Head DURATION 3 Study 4751 6Vein Condition May Mask Serious Clot Disorder 52152 1Vein Condition May Mask Serious Clot Disorder 52152 2
(Date:11/6/2009)...HAM, Mass. and SYDNEY, Nov. 6 /PRNewswire-FirstCal...WR ; ASX: HIN) a leading innovator and provider of...echnologies revolutionizing the treatment of advan...duled to make presentations at two upcoming invest...tation will be made at the Third Annual Canaccord ...
(Date:11/6/2009)... CPR is a simple but effective procedu...e first critical minutes of cardiac arrest. It pro...g enough to keep vital organs alive until professi...brillator) is an electronic device that can delive...mal heartbeat. AEDs are very accurate and easy to ...
(Date:11/6/2009)... The Recent NTSB Mandatory Sleep Apnea...Law Very Soon For Commercial Pilots And Drivers. I...Sleep Apnea Lab Testing Could Cost About $2,000 Wi... 60% Of Diagnosed Apnea Patients Can Not Tolerate ...aUSA.net Proposed An Immediate Alternative Solutio...
(Date:11/6/2009)... November is Alzheimer,s Awareness Mon...rt declares that more than 35 million people world...g Communities , an industry innovator with 16 inde...s/memory care communities in Wisconsin and Illinoi...t or delay the onset of Alzheimer,s disease. , ...
(Date:11/5/2009)...GE, Mass., Nov. 5 ETEX Corporation...y a distribution agreement with Alphatec Spine, of...and sell ETEX,s proprietary bone graft substitute ...tates. ,, (Logo: http://www.newscom.com/cgi...ales and marketing efforts will be focused on Equi...
Breaking Medicine News(10 mins):Health News:HeartWare to Present at Upcoming Investment Conferences in November 2Health News:A New Era of E-Learning in the Comfort and Convenience of Your Home or Office Without the Classroom Environment 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 2Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 3Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 4Health News:SleepApneaUSA.net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB's Sleep Apnea Testing Recommendations 5Health News:Top 10 Ways to Prevent or Delay Alzheimer's 2Health News:ETEX Corporation Announces Distribution Agreement with Alphatec Spine 2Health News:ETEX Corporation Announces Distribution Agreement with Alphatec Spine 3
...ngCedarsofRussia.org released research this month ... Cedar nuts, also known as Pinus Sibirica, has bee...trial conducted by Professor A. B. Krivosheev from...d. Pine nut oil was proven effective against the r...
...eople are used to the clutter in their homes getti...trash block hallways, the top of the bed has been ...never found) in the chaos, the disorganization may...nt Health, Balanced Living magazine,s January iss...
...known for delicious food, great,wine and beautiful...inventive,beef recipes. The 28th National Beef Co...during the peak of the area,s beautiful harvest se...n Francisco Bay Area,and Sacramento metropolitan a...
...Inc. (NYSE Alternext US: ADL), a vertically integr...na and the U.S., announced today it has revised it...on Plan for senior management and employees. , ,...centive plan. Incentives are based on successfull...
...., Jan. 8 Allscripts,announced today that Excela ...estern Pennsylvania, has selected the Allscripts E...ore than 115 physicians it employs in the Excela H...Westmoreland, Indiana, and Fayette,counties, inclu...
...en who had been followed for about 15 years , ... therapy may lower a woman,s risk of colorectal ca...rmones. , This new finding, published in the Janua...ement therapy (HRT). , Previous landmark research ...
Other Medicine News:Health News:RingingCedarsofRussia.org Releases Pine Nut Oil Research Showing That Digestive and Stomach Disorders Respond to Unique Super Food: Siberian Pine Nut Oil 2Health News:Is Clutter Making You Fat? Take Natural Solutions Magazine's Clutter Quiz and Get Home Organizing Tips for 2009 2Health News:28th National Beef Cook-Off(R) Seeks 'Sonoma-Style' Recipe Entries 2Health News:28th National Beef Cook-Off(R) Seeks 'Sonoma-Style' Recipe Entries 3Health News:AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan 2Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 2Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 3Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 4Health News:Excela Health Selects Allscripts Electronic Health Record for Physicians 5Health News:Hormone Therapy May Cut Colorectal Cancer Risk 2
PEACOCK
Linac Scalpel System
Platinum Plus
Clinac 21EX Platinum
Medicine Products: